Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology

William Blair analyst Matt Phipps has reiterated their neutral stance on BMY stock, giving a Hold rating yesterday.

Matt Phipps has given his Hold rating due to a combination of factors surrounding Bristol-Myers Squibb’s current position in the competitive landscape of hematology treatments. The company recently showcased a wide array of clinical programs, particularly in multiple myeloma and non-Hodgkin lymphoma, which are areas with increasing competition, especially from strong contenders like Johnson & Johnson.
Despite the promising potential of CELMoDs to be combined with T-cell engagers, and the encouraging early results from the MELT-MM trial, there remains uncertainty about how Bristol-Myers will maintain its competitive edge. The company has a series of milestones expected in 2026 that could clarify approval timelines and growth potential, but until these updates provide more clarity, the Hold rating reflects a cautious stance on the stock’s current valuation and future prospects.

Phipps covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Incyte, and Merus. According to TipRanks, Phipps has an average return of 4.5% and a 47.98% success rate on recommended stocks.

In another report released yesterday, Wells Fargo also maintained a Hold rating on the stock with a $55.00 price target.